Acrobat
PDF file can be downloaded here.
Although insulin was the
first endocrine hormone to be isolated and identified, its mechanism of action
is still only partially understood. Once more, I refer the reader to one
of the many excellent textbooks of medical biochemistry for a discussion of the
insulin receptor and its interaction with insulin. Let me just state
quickly that the hormone binds to its receptor which has both extra and
intracellular domains. Binding of insulin to the tetrameric receptor
initiates
tyrosine
protein kinase activity bringing about an autophosphorylation of the
intracellular domains of the receptor. This marks the beginning of a
phosphorylation cascade. When these processes were first identified in the
1970s, the following cartoon appeared in Trends in Biochemical Sciences (Pierre
de Metz, TIBS 1979). It gives a pretty good impression of the frustration
that many researches felt at that time. We knew that phosphorylation was
involved in insulin's action, but the specific substrates and relationship to
physiological processes remained in the dark.
Another observation that
caused a lot of speculation was that the insulin-receptor complexes merged in
the target cell's plasma membrane and gathered at clathrin-coated
"pits". These underwent endocytosis and uptake into endosomes
where the receptors and insulin parted company. The separated partners
were then sent to lysosomes and destruction. Later, it was found that
many of the receptors were reused, being sent back to the plasma membrane
from the endosomes after a little control-and-reparation visit in the Golgi
apparatus. Again, a great cartoon appeared in TIBS showing the
state of knowledge at that point (I have added the "receptor return
pathway").

Our
metabolism is controlled by so-called feedback mechanisms. Control sensors measure blood levels of
lipids, amino acids and sugar and send this information to hormone-secreting
cells. In all animals, insulin is THE
anabolic hormone, maintaining stores of energy and building these up after
meals. Glucagon, growth hormone,
adrenalin and noradrenalin oppose insulin’s
actions, freeing energy in the form of fatty acids or glucose when these are needed. Insulin’s main effects are summarized in the
following figure.

Insulin stimulates glucose uptake
in the liver, fat cells and skeletal muscle.
Glucose is stored as either glycogen in liver and muscle, or as
triglycerides in adipocytes. Important
actions of insulin include inhibition of lipolysis, glycogenolysis, and
gluconeogenesis. Insulin controls
metabolism from minute-to-minute. About
50% of that insulin released from beta cells during the day is NOT associated
with meals. Insulin and its “opposing
hormones” constantly control our metabolism to provide optimal efficiency.
3. Reactions
occurring independently of IRS phosphorylation.
The first group is mainly concerned with control of metabolism; the
second with steering of nuclear reactions and the third is involved with
glucose uptake and GLUT4 movement. These
are shown in the next figure.
Insulin is an anabolic hormone, causing cells to take
up energy substrates at times of excess.
Insulin action is countered by the catabolic hormones glucagon,
adrenalin and noradrenalin, and
growth hormone. These act primarily
through cyclic AMP (cAMP) and protein kinase A. Look at the figure below.
Glucose uptake to muscle and fat cells is dependent
upon activation of GLUT4. This system
fails when insulin secretion is no longer coupled to blood glucose levels. The liver’s uptake of glucose also drops off
because neither glycogen synthetase nor pyruvate dehydrogenase are activated by
insulin. The body reacts as though
glucose was not present.The best known of the many actions
of insulin is control of glucose transport over the plasma membrane of skeletal
muscle and fat cells. Remember, molecules as large as glucose (MW 180)
cannot simply diffuse through cell membranes (discussed here) .
Glucose transport protein 4 (GLUT4) carries out insulin-stimulated glucose
transport. It moves from inactive stores in the Golgi apparatus to the
plasma membrane following
insulin-receptor
interaction. GLUT4 is active as long as it is localized in the plasma
membrane.
It is important to realize
that muscular work (utilization of glucose and glycogen as energy substrates in
muscle) can also activate movement of GLUT4 to the plasma membrane.
Plasma insulin levels fall under conditions of hard work. Never the less,
glucose uptake into muscle cells increases under exercise due to the response
of the muscle cell to substrate use (Refer to the
earlier discussion of the effects of work on glucose transport).
Movement of GLUT4 to and from the plasma membrane requires the use of
ATP. Furthermore, movement of GLUT4 is dependent upon an intact
microtubular system: Cholchicine, a drug used in the treatment of gout,
binds to microtubular proteins and causes depolymerization of these.
Cholchicine blocks insulin activation of glucose transport in muscle and fat.
A recent publication
by Saltiel and Kahn demonstrated insulin's effect on GLUT4 in isolated fat
cells. They used a fluorescent antibody to mark GLUT4 and exposed cells
to insulin. You can clearly see that GLUT4 was restricted to an internal
region in the basal state that the GLUT4-
antibody
complex moved to the fat cell's outer membrane in the presence of insulin.
Insulin has many actions in
addition to regulation of glucose uptake by muscle and fat. Insulin is
strongly involved in regulation of cyclic AMP levels through its effects on
phosphodiesterase. Thus, insulin counters actions of the many hormones
that modify metabolism through activation of adenyl cyclase. Perhaps the
most important of these in regulation of homeostasis is glucagon. Insulin
reduces the rate of lipolysis and is a major element in regulation of hepatic
gluconeogenesis. Insulin activates amino acid uptake in most cells and is
necessary for activation of protein synthesis at the nuclear level.
Let us go back to Saltiel
and Kahn’s rather complex figure. Protein phosphorylation cascades are
involved in most of the actions of insulin. Hormone-receptor interaction
initiates an autophosphorylation of tyrosine residues on the intracellular
domain of the receptor. This triggers phosphorylation of serine residues
on a number of "insulin-receptor substrates" (IRS1-4 and
Gab-1). The phosphorylated substrates activate a series of small
"G-proteins" linked to gene expression and phosphoinositol 3-kinase
that directs metabolism. Thus, insulin controls gene expression, lipid,
protein and carbohydrate metabolism and cell growth and differentiation.
The
insulin receptor substrate proteins (IRS proteins) have been subject to further
investigation by Kahn and his associates. There are a series of studies
in mice with disruption of the IRS genes. Knockout of IRS-1 production
slows growth, but such mice do not develop diabetes in spite of development of
mild insulin resistance and glucose intolerance. Knockout of IRS-2 genes
gives only a slight effect upon growth. However IRS-2 deficient mice
develop insulin resistance and diabetes. The functions of IRS-3 and IRS-4
are less clearly defined. In a recent publication Kahn et al have studied
the effects of combined IRS-1/IRS-3 and IRS-1/IRS-4 deficiency in
mice. The first knockout pair IRS-1/IRS-3 resulted in severe
lipoatrophy. This depression of adipose tissue activity also resulted in
a major decrease in leptin production and release. Hyperglycemia
accompanied by high insulin levels was found in these animals. The
IRS-1/IRS-4 animals did not differ from mice lacking IRS-1. See Genes and
Development 16 3213-3222, 2003 for more information.
One of the many studies
aimed at finding a key common signal for insulin's many actions was published
in 1998 by Sheperd et.
al. (Biochemical J., 333, 471-490).
Here the authors summarize work that demonstrates that many of insulin's
actions appear follow activation of phosphoinositol 3-kinase, leading to
formation of phosphatidylinositol 3,4,5-trisphosphate
(PIP3) and phosphatidylinositol 3,4 bisphosphate [PI(3,4)P2].
It would appear that PIP3 is the more important of these. PIP3
is thought to act as a membrane anchor for elements in insulin's
mechanism of action as well as acting as an allosteric regulator in these
complex processes.
Insulin's effects on
phosphodiesterase seem to be independent of these mechanisms.
While this section may appear
to by way beyond the interests of second-year medical students it does present
data that is actively being pursued in an effort to discover new approaches to
treatment of diabetes.
Insulin-activation
of GLUT4 transport is mediated by GTP-binding proteins.
The various actions of
insulin have been shown to follow exceedingly complex mechanisms and the
transport of GLUT4 is no exception. An very informative publication has recently appeared in Molecular
and Cellular Endocrinology 235 (2005) 1-9, entitled Functional role of Rab11 in
GLUT4 trafficking in cardiomyocytes, M. Uhlig, W. Passlack ahd J. Eckel. This article presents an excellent review of
current knowledge about movement of the insulin-sensitive glucose transporter
and new findings about the role of GTP-binding proteins in these
processes. Their data show that one of
these, RAB11, is intimately involved in movement of GLUT4 in response to
insulin. Please go to the original
article if you wish to examine the details.
Glucagon is one of the many
hormones that act through activation of adenyl cyclase, increasing the level of
cyclic AMP in target cells. Glucagon receptors are found primarily in
adipose tissue (where the hormone initials lipolysis and release of fatty acids)
and the liver (where it promotes glucose release through activation of
glycogenolysis and gluconeogenesis). Skeletal muscle does not have
receptors for this hormone. Cyclic AMP
in general opposes insulin's diverse actions, and insulin action goes at least
partially through activation of phosphodiesterase and reduction of cAMP
levels. This is the basis for insulin's antilipolytic effect shown in the
figure above.
The increase in the rate of
lipolysis seen in diabetes is due to glucagon’s stimulation of
hormone-sensitive lipase and the simultaneous loss of the braking effect of
insulin on this enzyme. Hepatic
gluconeogenesis is accelerated in diabetes in spite of the high levels of
glucose in the blood. As stated above,
the body interprets the inability to transport glucose over cell membranes as a
lack of glucose. In
other words, as an energy crisis requiring mobilization of stored fat and
production of sugar in the liver.
Normalization of blood glucose levels in mild type 2
diabetes often can be achieved by diet and inhibition of hepatic
gluconeogenesis with metformin.